Onsdag 2 April | 13:03:43 Europe / Stockholm

Bifogade filer

Kalender

Est. tid*
2025-11-07 07:50 Kvartalsrapport 2025-Q3
2025-08-08 07:50 Kvartalsrapport 2025-Q2
2025-05-23 N/A X-dag ordinarie utdelning RAY B 3.00 SEK
2025-05-22 N/A Årsstämma
2025-05-09 07:50 Kvartalsrapport 2025-Q1
2025-02-21 - Bokslutskommuniké 2024
2024-11-08 - Kvartalsrapport 2024-Q3
2024-08-16 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag bonusutdelning RAY B 1.3
2024-05-23 - X-dag ordinarie utdelning RAY B 0.70 SEK
2024-05-22 - Årsstämma
2024-05-17 - Kvartalsrapport 2024-Q1
2024-02-23 - Bokslutskommuniké 2023
2023-11-17 - Kvartalsrapport 2023-Q3
2023-08-25 - Kvartalsrapport 2023-Q2
2023-05-26 - X-dag ordinarie utdelning RAY B 0.00 SEK
2023-05-25 - Årsstämma
2023-05-17 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2022-05-25 - Årsstämma
2022-05-18 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2021-05-26 - Årsstämma
2021-05-05 - Kvartalsrapport 2021-Q1
2021-02-23 - Bokslutskommuniké 2020
2020-11-18 - Kvartalsrapport 2020-Q3
2020-08-26 - Kvartalsrapport 2020-Q2
2020-07-01 - X-dag ordinarie utdelning RAY B 0.00 SEK
2020-06-30 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-20 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning RAY B 0.00 SEK
2019-05-21 - Årsstämma
2019-05-09 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-15 - Kvartalsrapport 2018-Q3
2018-08-23 - Kvartalsrapport 2018-Q2
2018-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2018-05-29 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-15 - Bokslutskommuniké 2017
2017-11-22 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-24 - X-dag ordinarie utdelning RAY B 0.00 SEK
2017-05-23 - Årsstämma
2017-05-19 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-18 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-18 - X-dag ordinarie utdelning RAY B 0.25 SEK
2016-05-17 - Årsstämma
2016-05-12 - Kvartalsrapport 2016-Q1
2016-02-18 - Bokslutskommuniké 2015
2015-11-25 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-05-29 - X-dag ordinarie utdelning RAY B 0.00 SEK
2015-05-28 - Årsstämma
2015-05-08 - Kvartalsrapport 2015-Q1
2015-02-12 - Bokslutskommuniké 2014
2014-11-27 - Kvartalsrapport 2014-Q3
2014-08-27 - Kvartalsrapport 2014-Q2
2014-05-28 - X-dag ordinarie utdelning RAY B 0.00 SEK
2014-05-27 - Årsstämma
2014-05-16 - Kvartalsrapport 2014-Q1
2014-02-13 - Bokslutskommuniké 2013
2013-11-27 - Kvartalsrapport 2013-Q3
2013-08-28 - Kvartalsrapport 2013-Q2
2013-05-23 - X-dag ordinarie utdelning RAY B 0.00 SEK
2013-05-22 - Årsstämma
2013-05-16 - Kvartalsrapport 2013-Q1
2013-02-14 - Bokslutskommuniké 2012
2012-11-16 - Kvartalsrapport 2012-Q3
2012-08-28 - Kvartalsrapport 2012-Q2
2012-05-31 - X-dag ordinarie utdelning RAY B 0.00 SEK
2012-05-30 - Årsstämma
2012-05-23 - Kvartalsrapport 2012-Q1
2012-02-16 - Bokslutskommuniké 2011
2011-11-24 - Kvartalsrapport 2011-Q3
2011-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2011-05-25 - Årsstämma
2011-05-04 - Kvartalsrapport 2011-Q1
2011-02-18 - Bokslutskommuniké 2010
2010-11-12 - Kvartalsrapport 2010-Q3
2010-08-27 - Kvartalsrapport 2010-Q2
2010-05-26 - X-dag ordinarie utdelning RAY B 0.50 SEK
2010-05-25 - Årsstämma
2010-05-11 - Kvartalsrapport 2010-Q1
2009-11-20 - Kvartalsrapport 2009-Q3
2009-08-27 - Kvartalsrapport 2009-Q2
2009-05-27 - X-dag ordinarie utdelning RAY B 0.00 SEK
2009-05-26 - Årsstämma
2009-05-15 - Kvartalsrapport 2009-Q1
2008-06-25 - Split RAY B 1:3
2003-06-10 - Split RAY B 20:1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av mjukvara för strålbehandling av cancer. Bolagets produkter riktar sig till sjukvårdsinstitutioner och onkologer. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. RaySearch Laboratories grundades 2000 och har sitt huvudkontor i Stockholm, Sverige.
2025-03-18 17:31:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE OR MAY BE UNLAWFUL. PLEASE REFER TO THE SECTION "IMPORTANT NOTICE" AT THE END OF THIS PRESS RELEASE.

The CEO, Founder and Board member of RaySearch Laboratories AB, Johan Löf (the "Seller"), announces his intention to sell approximately 2 million class B shares in RaySearch Laboratories AB (publ) ("RaySearch Laboratories" or the "Company"), corresponding to approximately 6 per cent of the total shares of the Company (the "Placing Shares") through a placing to institutional and other qualified investors (the "Placing").

The Placing is being conducted by way of an accelerated bookbuilding, which will be launched immediately following this announcement. Skandinaviska Enskilda Banken AB (publ) ("SEB") is acting as Sole Global Coordinator and Bookrunner on the transaction.

The Placing Shares will be converted from class A shares with the conversion being completed prior to settlement of the Placing. If all Placing Shares are sold, the Seller will hold approximately 3.4 million class A shares and 68,393 class B shares in the Company following the Placing, corresponding to approximately 10 per cent of the total shares and approximately 40 per cent of the votes in the Company. The Seller reserves the right, at his own discretion, to decide the number of shares to be sold, if any, in the Placing.

The Company's class B shares are listed on Nasdaq Stockholm, under the ticker RAY B.

Johan Löf founded RaySearch Laboratories in 2000 and is since its CEO and part of the Board. Over the last 25 years, Johan Löf has made some sell-downs but limited in size in relation to his overall ownership in the Company. The Placing is initiated for the purpose of providing liquidity to the Seller. Johan Löf remains highly committed to the Company and as such has entered into a 500-day lock-up commitment with SEB for his remaining shares in RaySearch Laboratories. Johan Löf will remain in his role as CEO as well as a Member of the Board of Directors of the Company.

The price and the total number of Placing Shares being sold in the Placing will be determined through the accelerated bookbuilding process carried out by SEB. The bookbuilding will commence immediately following the publication of this announcement and end before the commencement of trading on Nasdaq Stockholm on 19 March 2025. The bookbuilding may be cancelled, shortened or closed at any time on short notice at the sole discretion of SEB and the Seller. Further announcements will be made following completion of the bookbuilding.

SEB acts as Sole Global Coordinator and Bookrunner and Mannheimer Swartling acts as the Company's legal advisor and Baker & McKenzie Advokatbyrå acts as the Seller's legal advisor.

This information is information that RaySearch Laboratories AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out below, at 17:31 CET on the 18 March, 2025.

For additional information, please contact:

Johan Löf, CEO and Board Member

Phone: +46 70 683 79 35

Email: johan.lof@raysearchlabs.com

IMPORTANT NOTICE

THIS ANNOUNCEMENT IS NOT AN OFFER TO SELL, OR SOLICITATION OF AN OFFER TO BUY, ANY SECURITIES IN THE UNITED STATES. THE SECURITIES REFERRED TO HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT") AND MAY NOT BE SOLD IN THE UNITED STATES ABSENT REGISTRATION WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT. THERE IS NO INTENTION TO REGISTER ANY SECURITIES REFERRED TO HEREIN IN THE UNITED STATES OR TO CONDUCT A PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.

THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES OR INVESTMENTS FOR SALE OR A SOLICITATION OF AN OFFER TO BUY SECURITIES OR INVESTMENTS IN CANADA, JAPAN OR AUSTRALIA OR ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE UNLAWFUL. NO ACTION HAS BEEN TAKEN THAT WOULD PERMIT AN OFFERING OF THE SECURITIES OR POSSESSION OR DISTRIBUTION OF THIS ANNOUNCEMENT IN ANY JURISDICTION WHERE ACTION FOR THAT PURPOSE IS REQUIRED. PERSONS INTO WHOSE POSSESSION THIS ANNOUNCEMENT COMES ARE REQUIRED TO INFORM THEMSELVES ABOUT AND TO OBSERVE ANY SUCH RESTRICTIONS. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE SECURITIES LAWS OF ANY SUCH JURISDICTION.

WITH RESPECT TO THE MEMBER STATES OF THE EUROPEAN ECONOMIC AREA (EACH A "RELEVANT MEMBER STATE"), NO ACTION HAS BEEN UNDERTAKEN OR WILL BE UNDERTAKEN TO MAKE AN OFFER TO THE PUBLIC OF THE SECURITIES REFERRED TO HEREIN REQUIRING THE PUBLICATION OF A PROSPECTUS IN ANY RELEVANT MEMBER STATE. AS A RESULT, THESE SECURITIES MAY ONLY BE OFFERED OR SOLD IN ANY RELEVANT MEMBER STATE PURSUANT TO AN EXEMPTION UNDER REGULATION (EU) 2017/1129 (AS AMENDED OR SUPERSEDED, THE "PROSPECTUS REGULATION"). THIS ANNOUNCEMENT IS ONLY ADDRESSED TO, AND DIRECTED AT, PERSONS IN RELEVANT MEMBER STATES WHO ARE "QUALIFIED INVESTORS" WITHIN THE MEANING OF ARTICLE 2 (E) OF THE PROSPECTUS REGULATION ("QUALIFIED INVESTORS").

IN THE UNITED KINGDOM THIS ANNOUNCEMENT IS DIRECTED EXCLUSIVELY AT QUALIFIED INVESTORS AS DEFINED IN ARTICLE 2 OF THE PROSPECTUS REGULATION AS IT FORMS PART OF DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK PROSPECTUS REGULATION'') WHO ARE (I) "INVESTMENT PROFESSIONALS" FALLING WITHIN ARTICLE 19(5) OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (THE "ORDER"); OR (II) PERSONS FALLING WITHIN ARTICLE 49(2)(A) TO (D) ("HIGH NET WORTH COMPANIES, UNINCORPORATED ASSOCIATIONS ETC") OF THE ORDER, AND/OR (III) TO WHOM IT MAY OTHERWISE LAWFULLY BE COMMUNICATED UNDER THE ORDER, ALL SUCH PERSONS TOGETHER BEING REFERRED TO AS ("RELEVANT PERSONS"). UNDER NO CIRCUMSTANCES SHOULD PERSONS WHO ARE NOT RELEVANT PERSONS RELY OR ACT UPON THE CONTENTS OF THIS ANNOUNCEMENT. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IN THE UNITED KINGDOM IS AVAILABLE ONLY TO, AND WILL BE ENGAGED ONLY WITH, RELEVANT PERSONS.

IN CONNECTION WITH THE SHARE SALE, SEB AND ANY OF ITS AFFILIATES ACTING AS AN INVESTOR FOR ITS OWN ACCOUNT MAY TAKE UP AS A PRINCIPAL POSITION ANY SHARES AND IN THAT CAPACITY MAY RETAIN, PURCHASE OR SELL FOR ITS OWN ACCOUNT SUCH SHARES. IN ADDITION, SEB OR ITS AFFILIATES MAY ENTER INTO FINANCING ARRANGEMENTS AND SWAPS WITH INVESTORS IN CONNECTION WITH WHICH SEB (OR ITS AFFILIATES) MAY FROM TIME TO TIME ACQUIRE, HOLD OR DISPOSE OF SHARES. SEB DOES NOT INTEND TO DISCLOSE THE EXTENT OF ANY SUCH INVESTMENT OR TRANSACTIONS OTHERWISE THAN IN ACCORDANCE WITH ANY LEGAL OR REGULATORY OBLIGATION TO DO SO.

SEB IS ACTING ON BEHALF OF THE SELLER AND NO ONE ELSE IN CONNECTION WITH THE SHARE SALE AND WILL NOT BE RESPONSIBLE TO ANY OTHER PERSON FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF SEB OR FOR PROVIDING ADVICE IN RELATION TO THE SHARE SALE.